• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Perrigo Company plc

    3/21/25 7:00:04 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRGO alert in real time by email
    DEFA14A 1 prgo_2025_addl_materials.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

     

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant to §240.14a-12

     

    PERRIGO COMPANY PLC

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     


     

    img190069377_0.jpg

    Logo P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Shareholders Meeting To Be Held On May 1, 2025 For Shareholders of record as of March 3, 2025 To order paper materials, use one of the following methods. Internet: www.investorelections.com/PRGO Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Perrigo Company plc Annual Meeting of Shareholders Thursday, May 1, 2025 8:30 AM, Irish Standard Time 70 Sir John Rogerson's Quay, Grand Canal Dock, Dublin 2, D02 R296, Ireland For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/PRGO To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before April 18, 2025. SEE REVERSE FOR FULL AGENDA Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


     

    img190069377_1.jpg

    Logo Perrigo Company plc Annual Meeting of Shareholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR each nominee listed in Proposal 1 and FOR Proposals 2, 3, 4, 5, 6 and 7 PROPOSAL 1. To elect, by separate resolutions, eleven director nominees to serve until the 2026 Annual General Meeting of Shareholders; 1.01 Bradley A. Alford 1.02 Orlando D. Ashford 1.03 Julia M. Brown 1.04 Kevin Egan 1.05 Adriana Karaboutis 1.06 Jeffrey B. Kindler 1.07 Patrick Lockwood-Taylor 1.08 Albert A. Manzone 1.09 Donal O'Connor 1.10 Geoffrey M. Parker 1.11 Jonas Samuelson 2. To ratify, in a non-binding advisory vote, the appointment of Ernst & Young LLP as the Company's independent auditor, and authorize, in a binding vote, the Board of Directors, acting through the Audit Committee, to fix the remuneration of the auditor; 3. To provide advisory approval of the Company's executive compensation 4. To renew the Board's authority to issue shares under Irish law; 5. To renew the Board's authority to opt-out of statutory pre-emption rights under Irish law; 6. To approve an increase in the maximum number of directors who may be appointed to the Board; 7. To approve amendments to the Company's Articles of Association;


    Get the next $PRGO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRGO

    DatePrice TargetRatingAnalyst
    11/6/2025$20.00Overweight → Neutral
    Analyst
    1/14/2025Buy → Hold
    Argus
    1/6/2025$34.00 → $27.00Overweight → Neutral
    Piper Sandler
    9/24/2024$50.00 → $30.00Hold
    Jefferies
    11/17/2023$37.00Overweight
    Piper Sandler
    3/7/2023$49.00Buy
    Canaccord Genuity
    9/14/2022$46.00Hold → Buy
    Argus
    9/6/2022$48.00 → $54.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $PRGO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 13, 2023 - FDA Approves First Nonprescription Daily Oral Contraceptive

    For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor

    7/13/23 8:32:15 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Perrigo downgraded by Analyst with a new price target

    Analyst downgraded Perrigo from Overweight to Neutral and set a new price target of $20.00

    11/6/25 8:47:26 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo downgraded by Argus

    Argus downgraded Perrigo from Buy to Hold

    1/14/25 8:38:48 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Perrigo from Overweight to Neutral and set a new price target of $27.00 from $34.00 previously

    1/6/25 8:24:36 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Parker Geoffrey M. bought $106,350 worth of Ordinary Shares (7,500 units at $14.18) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    11/14/25 10:45:37 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP and CSO Lennox Abigail bought $28,125 worth of Ordinary Shares (1,255 units at $22.41) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/10/25 4:19:48 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel & Sec. Atkinson Charles bought $23,200 worth of Ordinary Shares (1,000 units at $23.20) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/9/25 3:47:36 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and CSO Lennox Abigail exercised 3,185 units of Ordinary Shares at a strike of $14.64 and covered exercise/tax liability with 1,660 units of Ordinary Shares, increasing direct ownership by 122% to 2,780 units (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    2/10/26 4:33:29 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Alford Bradley A

    4 - PERRIGO Co plc (0001585364) (Issuer)

    12/16/25 10:51:48 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Parker Geoffrey M.

    4 - PERRIGO Co plc (0001585364) (Issuer)

    12/16/25 10:44:39 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Perrigo Company plc

    SCHEDULE 13G - PERRIGO Co plc (0001585364) (Subject)

    2/5/26 2:31:15 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Perrigo Company plc

    SCHEDULE 13G/A - PERRIGO Co plc (0001585364) (Subject)

    11/14/25 12:19:22 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Perrigo Company plc

    10-Q - PERRIGO Co plc (0001585364) (Filer)

    11/5/25 3:20:40 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Perrigo to Attend Morgan Stanley Global Consumer & Retail Conference

    DUBLIN, Nov. 18, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of consumer health products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to participate in one-on-one investor meetings at the Morgan Stanley Global Consumer & Retail Conference on Tuesday, December 2nd, 2025. About Perrigo   Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. A

    11/18/25 8:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Reports Third Quarter 2025 Financial Results From Continuing Operations

    Amid Soft Market Consumption Trends, Achieved Q3 2025 Dollar, Unit and Volume Share(1) Gains in 5 of 7 Over-The-Counter ("OTC") Store Brand Categories and Dollar Share Gains in Key Brands Despite Marketplace Challenges, Delivered Meaningful YTD 2025 EPS Growth(2) with Gross and Operating Margin Expansion  Initiates Strategic Review of Infant Formula Business (Announced in Separate Press Release); Continues Strategic Review of Oral Care Business; On-Track to Close Previously Announced Sale of Dermacosmetics Business in Q1'26 Updates Full Year 2025 Outlook Due Primarily to Infant Formula Industry Dynamics and Soft OTC Market Consumption Trends DUBLIN, Nov. 5, 2025 /PRNewswire/ --

    11/5/25 6:35:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Perrigo Announces Global Operations and Supply Chain Leadership Transition

    Ron Janish, EVP Global Operations and Supply Chain, to Retire Industry Veteran, Matt Winterman, Appointed EVP Product Supply, Operations Strategy & Transformation Officer DUBLIN, June 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Both executives will closely work together to ensure a smooth tran

    6/4/25 8:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer

    Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and s

    1/6/25 8:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Financials

    Live finance-specific insights

    View All

    Perrigo Reports Third Quarter 2025 Financial Results From Continuing Operations

    Amid Soft Market Consumption Trends, Achieved Q3 2025 Dollar, Unit and Volume Share(1) Gains in 5 of 7 Over-The-Counter ("OTC") Store Brand Categories and Dollar Share Gains in Key Brands Despite Marketplace Challenges, Delivered Meaningful YTD 2025 EPS Growth(2) with Gross and Operating Margin Expansion  Initiates Strategic Review of Infant Formula Business (Announced in Separate Press Release); Continues Strategic Review of Oral Care Business; On-Track to Close Previously Announced Sale of Dermacosmetics Business in Q1'26 Updates Full Year 2025 Outlook Due Primarily to Infant Formula Industry Dynamics and Soft OTC Market Consumption Trends DUBLIN, Nov. 5, 2025 /PRNewswire/ --

    11/5/25 6:35:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo to Conduct Strategic Review of its Infant Formula Business

    DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO) ("Perrigo" or "the Company"), a leading provider of consumer health products, today announced that it is initiating a strategic review of its infant formula business. The review will assess a full range of alternatives. This review is aligned with Perrigo's 'Three-S' (Stabilize, Streamline, Strengthen) plan and reflects the Company's commitment to disciplined capital allocation and supporting improved return on invested capital and total shareholder return. It will focus on a combination of accelerating cash flows and reassessing the Company's previously announced investment in this business of $240 million, while optimizin

    11/5/25 6:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Announces Quarterly Dividend

    DUBLIN, Oct. 29, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of consumer health products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on December 16, 2025, to shareholders of record on November 28, 2025. About Perrigo Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market,

    10/29/25 11:57:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Perrigo Company plc

    SC 13G - PERRIGO Co plc (0001585364) (Subject)

    10/31/24 11:55:03 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Perrigo Company plc

    SC 13G - PERRIGO Co plc (0001585364) (Subject)

    2/13/24 1:05:29 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Perrigo Company plc (Amendment)

    SC 13G/A - PERRIGO Co plc (0001585364) (Subject)

    1/24/24 2:27:16 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care